LYCOS RETRIEVER Retriever Home  |  What is Lycos Retriever?  

1. Breast -- Breast Cancer
   Breast cancer is the second-most commonly diagnosed cancer in women, after skin cancer. About 215,990 American women will be diagnosed with breast cancer this year, according to the American Cancer Society. The disease will kill about 40,110 American women in 2004, according to the Centers for Disease Control and Prevention. To be eligible for the study, women need to be between 35 and 74 years old. Women who have not been diagnosed with breast cancer are eligible if a sister, living or dead, has had breast cancer. The women will be tracked for 10 years so researchers can study what links the few who get breast cancer compared with the majority who do not.
2. Cancer -- Breast Cancer
   Cancer screenings, such as mammography and breast examination for breast cancer and colonoscopy for colon cancer, may help catch these cancers at their early, most treatable stages. Some people at high risk for developing certain cancers can take medication to reduce their risk.
3. Femara -- Breast Cancers
   Letrozole (Femara) is one of a new group of drugs — called aromatase inhibitors — used to treat breast cancer. One potential side effect of aromatase inhibitors is bone loss (osteoporosis). You and your oncologist must weigh the risk of this medication worsening your osteoporosis against its potential benefits in treating your breast cancer.
4. Cristie Kerr -- Breast Cancer
   Professional golfer Cristie Kerr spends a lot of her time hitting the links. But she has devoted her heart to her breast cancer awareness foundation, Birdies for Breast Cancer. In addition to building the foundation on money from donations, pledges, and sponsors, Cristie herself donates $50 for every birdie she hits. Right now, that’s 319 and counting.
5. The Cure -- Breast Cancer
   The National Presenting Sponsor of the 2007 Komen Race for the Cure Series is Yoplait. Official Race Series Partners are American Airlines, Coldwater Creek(R), Energizer(R), Ford Division, New Balance Athletic Shoe, Inc. and Quilted Northern Ultra(R). The National Breast Cancer Survivor Recognition Program is co-sponsored by RE/MAX and Zeta Tau Alpha, and the Volunteer Recognition Program is sponsored by SunChips(R) brand.
6. Evista -- Breast Cancer
   The benefits and risks of taking Evista should be carefully weighed in each individual woman. Evista does not completely prevent breast cancer. Breast examinations and mammograms should be done before starting Evista and regularly thereafter.
7. Richard Roundtree -- Breast Cancer
   Roundtree was feeling so shocked after hearing the word, "cancer," that to this day he doesn’t remember how he broke the news to Karen who was waiting at home with their young daughters. Dr. Armstrong said they had found the cancer early. He was reassuring. But Roundtree, who says that no one else in his family has had breast cancer, thought he was going to die.
8. Zeneca Pharmaceuticals -- Breast Cancer
   With revenues of $14 billion, Zeneca is among the world's largest manufacturers of pesticides, plastics, and pharmaceuticals. Zeneca was instrumental in convincing the FDA to approve tamoxifen as a "prevention" measure to reduce the incidence of breast cancer in healthy women at risk. However, the World Health Organization's International Agency for Research on Cancer considers tamoxifen a "probable human carcinogen."
9. Herceptin -- Breast Cancers
   Trastuzumab (Herceptin®) is a monoclonal antibody. A monoclonal antibody is a protein that reacts with a specific site on a cell. Trastuzumab targets a protein called HER2. This protein is found on the surface of some types of cancer cells including prostate, colon, and ovarian cancers and 25—30% of breast cancer cells. Trastuzumab works by interfering with how these tumor cells grow and causes these cells to die. Generic trastuzumab injections are not available.
10. Nolvadex -- Breast Cancer
    Researchers from Italy recently conducted a clinical trial to determine if Nolvadex ® may reduce the risk of breast cancer in women at high-risk for developing the disease. The trial involved approximately 5,000 women who received either Nolvadex ® or placebo (inactive substitute) between 1992 and 1997. Upon initiation of this trial, women did not have breast cancer and had previously undergone a hysterectomy. Half of the women in this trial had ... previously had their ovaries removed.

« PreviousPage 1 of 108 Next »

SEARCH

Retriever Web